Vivani Medical: Strategic Innovation in GLP-1 Obesity Treatment Justifies Buy Rating
Vivani Medical (VANI) received a Buy rating from Maxim Group's Naz Rahman, who cited the company's innovative NanoPortal drug delivery platform and potential in the GLP-1 and obesity treatment market. The Phase 1 LIBERATE-1 study in Australia aims to assess the safety and effectiveness of the NPM-115 implant, with results expected in mid-2025. H.C. Wainwright also reiterated a Buy rating with a $3.00 price target. Corporate insider sentiment is positive.
Highlighted Terms
Related News
Vivani Medical (VANI) received a Buy rating from Maxim Group's Naz Rahman, who cited the company's innovative NanoPortal drug delivery platform and potential in the GLP-1 and obesity treatment market. The Phase 1 LIBERATE-1 study in Australia aims to assess the safety and effectiveness of the NPM-115 implant, with results expected in mid-2025. H.C. Wainwright also reiterated a Buy rating with a $3.00 price target. Corporate insider sentiment is positive.